Pfizer’s Lipitor® (Atorvastatin) was the best-selling pharmaceutical of all time totaling well over $125 billion in sales, prior to becoming generic. Even today, Atorvastatin represents almost half of the estimated $22 billion statin market in the United States.1
Indication BioScience’s Atorva+ formulation combines an FDA-approved small molecule with Atorvastatin, with an opportunity to create a new improved fixed-dose combination that may have advantages for patients. Indication BioScience also intends to develop additional combination statins including Rosuvastatin, Simvastatin, and Lovastatin.
Atorva+ has demonstrated in early pre-clinical animal models that it may reverse the statin-induced side effects
Both active ingredients in Atorva+ are already FDA-approved, allowing for accelerated approval pathway 505b2
Copyright © 2023 Indication BioScience, LLC - All Rights Reserved.